148 related articles for article (PubMed ID: 31046118)
1. Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical study.
Wang G; Chen C; Pai P; Korangath P; Sun S; Merino VF; Yuan J; Li S; Nie G; Stearns V; Sukumar S
Carcinogenesis; 2019 Jul; 40(7):903-913. PubMed ID: 31046118
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
Wardell SE; Yllanes AP; Chao CA; Bae Y; Andreano KJ; Desautels TK; Heetderks KA; Blitzer JT; Norris JD; McDonnell DP
Breast Cancer Res Treat; 2020 Jan; 179(1):67-77. PubMed ID: 31562570
[TBL] [Abstract][Full Text] [Related]
4. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
5. Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.
Yoshida T; Jin K; Song H; Park S; Huso DL; Zhang Z; Liangfeng H; Zhu C; Bruchertseifer F; Morgenstern A; Sgouros G; Sukumar S
Oncotarget; 2016 May; 7(22):33306-15. PubMed ID: 27119227
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors.
Cañas A; López-Sánchez LM; Valverde-Estepa A; Hernández V; Fuentes E; Muñoz-Castañeda JR; López-Pedrera C; De La Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
Breast Cancer Res; 2012 Dec; 14(6):R153. PubMed ID: 23216744
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
[TBL] [Abstract][Full Text] [Related]
9. Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study.
Wang G; Kumar A; Ding W; Korangath P; Bera T; Wei J; Pai P; Gabrielson K; Pastan I; Sukumar S
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2200200119. PubMed ID: 35675429
[TBL] [Abstract][Full Text] [Related]
10. Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
Fowler AM; Chan SR; Sharp TL; Fettig NM; Zhou D; Dence CS; Carlson KE; Jeyakumar M; Katzenellenbogen JA; Schreiber RD; Welch MJ
J Nucl Med; 2012 Jul; 53(7):1119-26. PubMed ID: 22669982
[TBL] [Abstract][Full Text] [Related]
11. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen Initiation After Ductal Carcinoma In Situ.
Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
[TBL] [Abstract][Full Text] [Related]
13. Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
Yu L; Wang L; Mao C; Duraki D; Kim JE; Huang R; Helferich WG; Nelson ER; Park BH; Shapiro DJ
Cancer Lett; 2019 Feb; 442():373-382. PubMed ID: 30419347
[TBL] [Abstract][Full Text] [Related]
14. Expression pattern and methylation of estrogen receptor α in breast intraductal proliferative lesions.
Mao X; Qiao Z; Fan C; Guo A; Yu X; Jin F
Oncol Rep; 2016 Oct; 36(4):1868-74. PubMed ID: 27498697
[TBL] [Abstract][Full Text] [Related]
15. PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ERα stability.
Jia W; Wu Q; Shen M; Yu X; An S; Zhao L; Huang G; Liu J
Cell Signal; 2024 Jul; 119():111184. PubMed ID: 38640982
[TBL] [Abstract][Full Text] [Related]
16. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
17. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Weir HM; Bradbury RH; Lawson M; Rabow AA; Buttar D; Callis RJ; Curwen JO; de Almeida C; Ballard P; Hulse M; Donald CS; Feron LJ; Karoutchi G; MacFaul P; Moss T; Norman RA; Pearson SE; Tonge M; Davies G; Walker GE; Wilson Z; Rowlinson R; Powell S; Sadler C; Richmond G; Ladd B; Pazolli E; Mazzola AM; D'Cruz C; De Savi C
Cancer Res; 2016 Jun; 76(11):3307-18. PubMed ID: 27020862
[TBL] [Abstract][Full Text] [Related]
18. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
19. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
20. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
